Prescription for treating pneumonia infected by novel coronavirus and application thereof

34 min read Original article ↗
Prescription for treating pneumonia infected by novel coronavirus and application thereof Download PDF

Info

Publication number
CN110870402A
CN110870402A CN202010081961.5A CN202010081961A CN110870402A CN 110870402 A CN110870402 A CN 110870402A CN 202010081961 A CN202010081961 A CN 202010081961A CN 110870402 A CN110870402 A CN 110870402A
Authority
CN
China
Prior art keywords
parts
prescription
ginger
chinese medicine
pneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010081961.5A
Other languages
Chinese (zh)
Other versions
CN110870402B (en
Inventor
葛又文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010081961.5A priority Critical patent/CN110870402B/en
Publication of CN110870402A publication Critical patent/CN110870402A/en
Application granted granted Critical
Publication of CN110870402B publication Critical patent/CN110870402B/en
Priority to KR1020227028314A priority patent/KR20220137663A/en
Priority to CA3168659A priority patent/CA3168659A1/en
Priority to JP2022546454A priority patent/JP7424684B2/en
Priority to PCT/CN2021/073829 priority patent/WO2021155751A1/en
Priority to TW110103119A priority patent/TWI792162B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a traditional Chinese medicine composition, and particularly discloses a prescription for treating pneumonia caused by novel coronavirus infection and application thereof. The raw materials of the prescription comprise the following traditional Chinese medicine materials in parts by weight: 9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb. The invention combines the pneumonia symptom expression of the novel coronavirus (2019-nCoV) infection, optimizes and fuses the traditional Chinese medicine formula, and treats the pneumonia together. From the prior treatment conditions of patients with confirmed diagnosis at different ages, a plurality of provinces and a plurality of places, the curative effect is definite, and the effective rate of the treatment reaches 95.12 percent.

Description

一种治疗新型冠状病毒感染的肺炎的方剂及其应用A kind of prescription for treating pneumonia infected by novel coronavirus and its application

技术领域technical field

本发明涉及中药组合物，具体地说，涉及一种治疗新型冠状病毒感染的肺炎的方剂。The present invention relates to traditional Chinese medicine compositions, in particular, to a prescription for treating pneumonia caused by novel coronavirus infection.

背景技术Background technique

2019新型冠状病毒，临时名称为2019-nCoV冠状病毒，是2019年在人体中发现的冠状病毒新毒株。该病毒症状一般为发热、乏力、干咳、逐渐出现呼吸困难，严重者表现为急性呼吸窘迫综合征，脓毒症休克，难以纠正的代谢性酸中毒和凝血功能障碍。该病毒已确认存在人传人现象，潜伏期具有传染性，所致疾病没有特异治疗方法。The 2019 novel coronavirus, tentatively named 2019-nCoV coronavirus, is a new strain of coronavirus discovered in humans in 2019. Symptoms of the virus are generally fever, fatigue, dry cough, and progressive dyspnea, and in severe cases, acute respiratory distress syndrome, septic shock, metabolic acidosis that is difficult to correct, and coagulation dysfunction. The virus has been confirmed to have human-to-human transmission, the incubation period is contagious, and there is no specific treatment for the disease.

发明内容SUMMARY OF THE INVENTION

为了解决现有技术中存在的问题，本发明的目的是提供一种治疗新型冠状病毒感染的肺炎的方剂(清肺排毒汤)及其应用。In order to solve the problems existing in the prior art, the purpose of the present invention is to provide a prescription (Qingfei Paidu Decoction) for the treatment of pneumonia caused by novel coronavirus infection and its application.

为了实现本发明目的，本发明的技术方案如下：In order to realize the purpose of the present invention, the technical scheme of the present invention is as follows:

第一方面，本发明提供一种治疗新型冠状病毒感染的肺炎的方剂，其原料包括如下重量份的中药材料：First aspect, the present invention provides a kind of prescription for the treatment of the pneumonia of novel coronavirus infection, and its raw material comprises the traditional Chinese medicine material of following weight portion:

麻黄8-10份、炙甘草5-8份、杏仁8-10份、生石膏15-30份、桂枝8-10份、泽泻8-10份、猪苓8-10份、白术8-10份、茯苓15份、柴胡15-18份、黄芩5-8份、姜半夏8-10份、生姜8-10份、紫苑8-10份、冬花8-10份、射干8-10份、细辛5-8份、山药10-14份、枳实5-8份、陈皮5-8份、藿香8-10份。8-10 parts of ephedra, 5-8 parts of Zhigancao, 8-10 parts of almond, 15-30 parts of raw gypsum, 8-10 parts of cinnamon, 8-10 parts of Alisma, 8-10 parts of Polyporus, Atractylodes 8-10 parts 15 parts of Poria, 15-18 parts of Bupleurum, 5-8 parts of Scutellaria, 8-10 parts of Ginger Pinellia, 8-10 parts of Ginger, 8-10 parts of Aster, 8-10 parts of Winter Flower, 8-10 parts of Shegan, 5-8 parts of Asarum, 10-14 parts of yam, 5-8 parts of Citrus aurantium, 5-8 parts of tangerine peel, 8-10 parts of Huoxiang.

作为优选，所述方剂的原料包括如下重量份的中药材料：麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。Preferably, the raw materials of the prescription include the following Chinese medicinal materials by weight: 9 parts of ephedra, 6 parts of Zhigancao, 9 parts of almonds, 15-30 parts of raw gypsum, 9 parts of cinnamon sticks, 9 parts of Alisma orientalis, 9 parts of Polyporus chinensis, Atractylodes 9 parts, Poria 15 parts, Bupleurum 16 parts, Scutellaria baicalensis 6 parts, Ginger Pinellia 9 parts, Ginger 9 parts, Aster 9 parts, Donghua 9 parts, Shegan 9 parts, Asarum 6 parts, Chinese yam 12 parts, Citrus citrus 6 parts parts, 6 parts of dried tangerine peel, and 9 parts of Huoxiang.

本发明所述方剂的组方，参考中医经典著作汉代张仲景《伤寒杂病论》，由麻黄杏仁甘草石膏汤(简称麻杏石甘汤，伤寒论63)、小柴胡汤(伤寒论96)、五苓散(伤寒论71)、射干麻黄汤(金匮要略.肺萎肺痈咳嗽上气病脉证治第七)加减化裁而成。方中的山药、枳实、陈皮和藿香，是针对本次新型冠状病毒感染的肺炎临床症状加减。The composition of the prescription of the present invention, with reference to Zhang Zhongjing's "Treatise on Febrile Diseases and Miscellaneous Diseases" in the Han Dynasty, a classic Chinese medicine, is composed of Mahuang Xingxinggancaojiaotang (referred to as Maxing Shigan Decoction, Shanghan Lun 63), Xiaochaihu Decoction (Shanghan Lun 96), Wuling Powder (Treatise on Febrile Diseases 71), Shegan Mahuang Decoction (Jinkui Yaolue. Lung atrophy, abscess, cough, upper qi disease, pulse syndrome seventh) are added and subtracted. The yam, citrus aurantium, tangerine peel and huoxiang in the recipe are for the addition and subtraction of the clinical symptoms of pneumonia caused by the new coronavirus infection.

其中，麻杏石甘汤宣肺透邪；五苓散化湿祛浊，通利三焦，湿走小便，使得湿气从毛孔与小便尽除；小柴胡汤梳理少阳枢机；射干麻黄汤解表化饮下气止咳；藿香、枳实、陈皮调理脾胃气机，芳香行气化浊，使得胸腹部浊气排除而呼吸顺畅；更有山药补益脾肾，扶助正气。全方共奏祛湿化浊，清肺透邪、调和气机之效。Among them, Maxing Shigan Decoction dispels the lungs and removes pathogenic factors; Wuling Powder disperses dampness and removes turbidity, clears the triple burner, and urinates when wet, so that moisture can be completely removed from pores and urination; Xiaochaihu Decoction combs Shaoyang cardinals; Shegan Mahuang Decoction dissolves Table Hua Yin Xia Qi relieves cough; Huoxiang, Citrus aurantium, tangerine peel regulate the spleen and stomach qi machine, fragrant qi and turbidity, make the chest and abdomen turbid qi expel and smooth breathing; more yam nourishes the spleen and kidney, and supports healthy qi. The whole recipe has the effect of removing dampness and turbidity, clearing the lungs and removing pathogens, and reconciling the qi.

进一步优选，所述方剂的中药原料由如下重量份的中药材料组成：Further preferably, the traditional Chinese medicine raw material of described prescription is made up of the traditional Chinese medicine material of following weight portion:

麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。9 parts of ephedra, 6 parts of Zhigancao, 9 parts of almonds, 15-30 parts of gypsum, 9 parts of cinnamon, 9 parts of Alisma, 9 parts of Polyporus, 9 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 9 parts of ginger, 9 parts of aster, 9 parts of winter flower, 9 parts of shegan, 6 parts of asarum, 12 parts of yam, 6 parts of citrus aurantium, 6 parts of tangerine peel, and 9 parts of Huoxiang.

其中，生石膏的用量依据患者是否发烧进行调整，如果患者不发烧则生石膏的用量要小，如果患者发烧或壮热则加大生石膏的用量。Among them, the dosage of gypsum is adjusted according to whether the patient has a fever. If the patient does not have a fever, the dosage of the gypsum should be smaller, and if the patient has a fever or strong fever, the dosage of the gypsum is increased.

进一步地，所述方剂的剂型为水煎剂。Further, the dosage form of the prescription is a water decoction.

第二方面，本发明提供了所述方剂的制备方法：将所述原料用水煎制，其中，生石膏先煎煮，再将其他中药材料(中药饮片)投入合并煎煮。In the second aspect, the present invention provides a method for preparing the formula: decoct the raw materials with water, wherein the raw gypsum is first decocted, and then other traditional Chinese medicine materials (Chinese herbal pieces) are put into and combined for decoction.

第三方面，本发明提供了所述方剂(清肺排毒汤)在制备具有清肺排毒药效的药物中的应用。In a third aspect, the present invention provides the application of the prescription (Qingfei Paidu Decoction) in preparing a medicine with the effect of clearing the lung and detoxifying.

以及，所述方剂(清肺排毒汤)在制备治疗肺炎疾病的药物中的应用。And, the application of the prescription (Qingfei Paidu Decoction) in the preparation of a medicine for treating pneumonia.

尤其是，所述肺炎为由病毒感染所致的肺炎。In particular, the pneumonia is pneumonia caused by viral infection.

所述病毒包括但不限于新型冠状病毒2019-nCoV、呼吸系统综合症冠状病毒及呼吸道合胞病毒。The viruses include but are not limited to novel coronavirus 2019-nCoV, respiratory syndrome coronavirus and respiratory syncytial virus.

经客观实验证实，本发明所述方剂对新型冠状病毒2019-nCoV感染引发的肺炎具有良好的治疗效果。Objective experiments have confirmed that the prescription of the present invention has a good therapeutic effect on pneumonia caused by novel coronavirus 2019-nCoV infection.

作为推荐，所述方剂的使用方法为：水煎服，一天一副，早晚两次(饭后四十分钟)，温服。如有条件，每副药服用后服大米汤半碗，舌干津液亏虚者可多服至一碗。三副一个疗程。建议患者须按原方服满一个疗程，若症状好转而未痊愈则服用第二个疗程。若患者有特殊情况或其他基础病，第二疗程可以根据实际情况修改处方，症状消失则停药。As a recommendation, the use method of the prescription is: decoct in water, take one pair a day, twice in the morning and evening (forty minutes after meals), and take it warm. If conditions permit, take half a bowl of rice soup after taking each pair of medicines, and those with dry tongue and body fluid deficiency can take one more bowl. Three sets of one course of treatment. It is recommended that patients should take the original prescription for a full course of treatment. If the patient has special conditions or other underlying diseases, the second course of treatment can modify the prescription according to the actual situation, and stop the drug if the symptoms disappear.

另外，服用此方前若有便秘现象，须加服防风通圣丸，大便通利后停服丸药。In addition, if there is constipation before taking this prescription, you must take Fangfengtongsheng pills, and stop taking the pills after the bowel movement is clear.

本发明涉及到的原料或试剂均为普通市售产品，涉及到的操作如无特殊说明均为本领域常规操作。The raw materials or reagents involved in the present invention are all common commercially available products, and the operations involved are routine operations in the art unless otherwise specified.

在符合本领域常识的基础上，上述各优选条件，可以相互组合，得到具体实施方式。On the basis of common knowledge in the art, the above preferred conditions can be combined with each other to obtain specific embodiments.

本发明的有益效果在于：The beneficial effects of the present invention are:

本发明结合本次“新型冠状病毒肺炎”的疫病症状表现，认为新型冠状病毒(2019-nCoV)感染的肺炎属于中医“寒疫”范畴，且湿邪为盛。主要病位在肺，其次病位在表卫、脾胃；主要病因为伏燥和湿寒邪气夹杂。主要病机为疫毒湿寒与伏燥搏结，导致气机痹阻，升降失常。Combined with the symptoms of the "new coronavirus pneumonia" this time, the present invention believes that the pneumonia infected by the new coronavirus (2019-nCoV) belongs to the category of "cold epidemic" in traditional Chinese medicine, and dampness is prevalent. The main disease site is in the lungs, followed by the external defense, spleen and stomach. The main pathogenesis is the dampness and coldness of the epidemic poison and the stagnation of dryness, which leads to the obstruction of the qi machine and the abnormal rise and fall.

本发明据此提供了前述方剂，利用多种中药优化融合，共同施治。从目前多省多地不同年龄层次的确诊患者救治情况看，疗效确切。相关临床观察研究持续进行中。Accordingly, the present invention provides the aforementioned prescription, which utilizes a variety of traditional Chinese medicines for optimal fusion and joint treatment. Judging from the current treatment of confirmed patients of different ages in many provinces and places, the curative effect is definite. Relevant clinical observational studies are ongoing.

本发明所提供的方剂(清肺排毒汤)为国家中医药管理局应急科研专项“中医药防治新型冠状病毒感染的肺炎有效方剂临床筛选研究”所使用方剂，目前正结合临床救治开展临床观察工作，相关研究正持续推进。该方适用于轻型、普通型、重型患者，在危重型患者救治中也可结合患者实际情况合理使用，具有良好的社会效益。The formula (Qingfei Paidu Decoction) provided by the present invention is the formula used in the emergency scientific research project of the State Administration of Traditional Chinese Medicine "Clinical Screening Research on Effective Prescriptions for Prevention and Treatment of Novel Coronavirus Infected Pneumonia" by Traditional Chinese Medicine, and is currently carrying out clinical observation work in combination with clinical treatment. , and related research is continuing. This prescription is suitable for light, ordinary and severe patients, and can also be reasonably used in the treatment of critically ill patients in combination with the actual situation of the patients, and has good social benefits.

具体实施方式Detailed ways

下面将结合实施例对本发明的优选实施方式进行详细说明。需要理解的是以下实施例的给出仅是为了起到说明的目的，并不是用于对本发明的范围进行限制。本领域的技术人员在不背离本发明的宗旨和精神的情况下，可以对本发明进行各种修改和替换。The preferred embodiments of the present invention will be described in detail below with reference to the examples. It should be understood that the following examples are given for illustrative purposes only, and are not intended to limit the scope of the present invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from the spirit and spirit of the present invention.

下述实施例中所使用的实验方法如无特殊说明，均为常规方法。The experimental methods used in the following examples are conventional methods unless otherwise specified.

下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。The materials, reagents, etc. used in the following examples can be obtained from commercial sources unless otherwise specified.

实施例1Example 1

本实施例用于说明本发明所述方剂(清肺排毒汤)的制备方法。This example is used to illustrate the preparation method of the formula (Qingfei Paidu Decoction) of the present invention.

一、原料(以重量份计)：1. Raw materials (by weight):

麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。9 parts of ephedra, 6 parts of Zhigancao, 9 parts of almonds, 15-30 parts of gypsum, 9 parts of cinnamon, 9 parts of Alisma, 9 parts of Polyporus, 9 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 9 parts of ginger, 9 parts of aster, 9 parts of winter flower, 9 parts of shegan, 6 parts of asarum, 12 parts of yam, 6 parts of citrus aurantium, 6 parts of tangerine peel, and 9 parts of Huoxiang.

其中，生石膏的用量依据患者是否发烧在上述用量范围内进行调整，如果患者不发烧则生石膏的用量要小，如果患者发烧或壮热则加大生石膏的用量。Among them, the dosage of gypsum is adjusted within the above dosage range according to whether the patient has a fever. If the patient does not have a fever, the dosage of the gypsum should be smaller, and if the patient has a fever or strong fever, the dosage of the gypsum is increased.

二，制备方法Second, the preparation method

按照上述重量配比称取原料(中药饮片)，先将生石膏置于水中煎煮，再将其他原料(中药饮片)投入合并煎煮。Weigh the raw materials (Chinese herbal medicine pieces) according to the above weight ratio, put the gypsum in water for decoction first, and then put other raw materials (Chinese herbal medicine pieces) into the mixture for decocting.

煎煮完成后，即得本发明所述方剂(清肺排毒汤)。After the decoction is completed, the prescription of the present invention (Qingfei Paidu Decoction) is obtained.

实验例1Experimental example 1

对新型冠状病毒感染的肺炎确诊病例给予实施例1制备的方剂(清肺排毒汤)尝试治疗。The prescription (Qingfei Paidu Decoction) prepared in Example 1 was given to the confirmed cases of pneumonia infected by the new coronavirus to try to treat.

水煎服，一天一副，早晚两次(饭后四十分钟)，温服。如有条件，每副药服用后服大米汤半碗，舌干津液亏虚者可多服至一碗。三副一个疗程。Decoct in water, one pair a day, twice in the morning and evening (forty minutes after meals), warm. If conditions permit, take half a bowl of rice soup after taking each pair of medicines, and those with dry tongue and body fluid deficiency can take one more bowl. Three sets of one course of treatment.

截至2月5日，该方剂已在四个省36个城市37个医院246名新型冠状病毒感染的肺炎确诊病例使用，通过对乏力、发烧、咳嗽、咽痛、纳差以及影像学等症状变化情况进行综合观察，数据显示：As of February 5, the prescription has been used in 246 confirmed cases of pneumonia caused by new coronavirus infection in 37 hospitals in 36 cities in four provinces. Comprehensive observation of the situation, the data shows:

234名患者服药后有效，总有效率约为95.12％。其中，81名患者服药后症状平稳未加重，约占总观察病例的32.93％；119名患者症状改善，约占总观察病例的48.37％；24名患者症状消失，约占总观察病例的9.76％；10名患者解除隔离或出院，约占总观察病例的4.07％。234 patients were effective after taking the medicine, and the total effective rate was about 95.12%. Among them, 81 patients had stable symptoms without aggravation after taking the drug, accounting for about 32.93% of the total observation cases; 119 patients had symptoms improved, accounting for about 48.37% of the total observation cases; 24 patients had symptoms disappeared, accounting for about 9.76% of the total observation cases ; 10 patients were released from isolation or discharged, accounting for about 4.07% of the total observed cases.

病情继续发展的患者有12名(4.88％)。There were 12 patients (4.88%) whose disease continued to develop.

实施例2Example 2

本实施例与实施例1的区别在于：The difference between this embodiment and Embodiment 1 is:

原料(以重量份计)：Raw materials (in parts by weight):

麻黄8份、炙甘草7份、杏仁10份、生石膏15-30份、桂枝8份、泽泻10份、猪苓10份、白术8份、茯苓14份、柴胡15份、黄芩7份、姜半夏10份、生姜8份、紫苑10份、冬花8份、射干10份、细辛5份、山药13份、枳实5份、陈皮7份、藿香10份。8 parts of ephedra, 7 parts of Zhigancao, 10 parts of almond, 15-30 parts of gypsum, 8 parts of cinnamon, 10 parts of Alisma, 10 parts of Polyporus, 8 parts of Atractylodes, 14 parts of Poria, 15 parts of Bupleurum, 7 parts of Scutellaria baicalensis , 10 parts of ginger pinellia, 8 parts of ginger, 10 parts of aster, 8 parts of winter flower, 10 parts of Shegan, 5 parts of Asarum, 13 parts of Chinese yam, 5 parts of Citrus aurantium, 7 parts of tangerine peel, 10 parts of Huoxiang.

实施例3Example 3

本实施例与实施例1的区别在于：The difference between this embodiment and Embodiment 1 is:

原料(以重量份计)：Raw materials (in parts by weight):

麻黄10份、炙甘草6份、杏仁8份、生石膏15-30份、桂枝10份、泽泻8份、猪苓8份、白术10份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑8份、冬花9份、射干10份、细辛6份、山药12份、枳实6份、陈皮5份、藿香8份。10 parts of ephedra, 6 parts of Zhigancao, 8 parts of almond, 15-30 parts of gypsum, 10 parts of cinnamon, 8 parts of Alisma, 8 parts of Polyporus, 10 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 9 parts of ginger, 8 parts of aster, 9 parts of winter flower, 10 parts of shegan, 6 parts of asarum, 12 parts of yam, 6 parts of citrus aurantium, 5 parts of tangerine peel, 8 parts of Huoxiang.

实施例4Example 4

本实施例与实施例1的区别在于：The difference between this embodiment and Embodiment 1 is:

原料(以重量份计)：Raw materials (in parts by weight):

麻黄9份、炙甘草6份、杏仁10份、生石膏15-30份、桂枝9份、泽泻9份、猪苓10份、白术10份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜8份、紫苑9份、冬花10份、射干9份、细辛6份、山药12份、枳实5份、陈皮6份、藿香9份。9 parts of ephedra, 6 parts of Zhigancao, 10 parts of almonds, 15-30 parts of gypsum, 9 parts of cinnamon, 9 parts of Alisma, 10 parts of Polyporus, 10 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 8 parts of ginger, 9 parts of aster, 10 parts of winter flowers, 9 parts of shegan, 6 parts of asarum, 12 parts of yam, 5 parts of citrus aurantium, 6 parts of tangerine peel, and 9 parts of Huoxiang.

虽然，上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。Although the present invention has been described in detail above with general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made on the basis of the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention fall within the scope of the claimed protection of the present invention.

Claims (9)

1.一种治疗新型冠状病毒感染的肺炎的方剂，其特征在于，其原料包括如下重量份的中药材料：1. a prescription for treating the pneumonia of novel coronavirus infection is characterized in that, its raw material comprises the Chinese medicine material of following weight portion: 麻黄8-10份、炙甘草5-8份、杏仁8-10份、生石膏15-30份、桂枝8-10份、泽泻8-10份、猪苓8-10份、白术8-10份、茯苓15份、柴胡15-18份、黄芩5-8份、姜半夏8-10份、生姜8-10份、紫苑8-10份、冬花8-10份、射干8-10份、细辛5-8份、山药10-14份、枳实5-8份、陈皮5-8份、藿香8-10份。8-10 parts of ephedra, 5-8 parts of Zhigancao, 8-10 parts of almond, 15-30 parts of raw gypsum, 8-10 parts of cinnamon, 8-10 parts of Alisma, 8-10 parts of Polyporus, Atractylodes 8-10 parts 15 parts of Poria, 15-18 parts of Bupleurum, 5-8 parts of Scutellaria, 8-10 parts of Ginger Pinellia, 8-10 parts of Ginger, 8-10 parts of Aster, 8-10 parts of Winter Flower, 8-10 parts of Shegan, 5-8 parts of Asarum, 10-14 parts of yam, 5-8 parts of Citrus aurantium, 5-8 parts of tangerine peel, 8-10 parts of Huoxiang. 2.根据权利要求1所述的方剂，其特征在于，其原料包括如下重量份的中药材料：2. prescription according to claim 1, is characterized in that, its raw material comprises the traditional Chinese medicine material of following weight portion: 麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。9 parts of ephedra, 6 parts of Zhigancao, 9 parts of almonds, 15-30 parts of gypsum, 9 parts of cinnamon, 9 parts of Alisma, 9 parts of Polyporus, 9 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 9 parts of ginger, 9 parts of aster, 9 parts of winter flower, 9 parts of shegan, 6 parts of asarum, 12 parts of yam, 6 parts of citrus aurantium, 6 parts of tangerine peel, and 9 parts of Huoxiang. 3.根据权利要求2所述的方剂，其特征在于，其中药原料由如下重量份的中药材料组成：3. prescription according to claim 2, is characterized in that, wherein medicine raw material is made up of the traditional Chinese medicine material of following weight portion: 麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。9 parts of ephedra, 6 parts of Zhigancao, 9 parts of almonds, 15-30 parts of gypsum, 9 parts of cinnamon, 9 parts of Alisma, 9 parts of Polyporus, 9 parts of Atractylodes, 15 parts of Poria, 16 parts of Bupleurum, 6 parts of Scutellaria baicalensis , 9 parts of ginger pinellia, 9 parts of ginger, 9 parts of aster, 9 parts of winter flower, 9 parts of shegan, 6 parts of asarum, 12 parts of yam, 6 parts of citrus aurantium, 6 parts of tangerine peel, and 9 parts of Huoxiang. 4.根据权利要求1-3任一项所述的方剂，其特征在于，所述方剂的剂型为水煎剂。4. The prescription according to any one of claims 1-3, wherein the dosage form of the prescription is a decoction. 5.权利要求1-4任一项所述方剂的制备方法，其特征在于，将所述原料用水煎制，其中，生石膏先煎煮，再将其他中药材料投入合并煎煮。5. The preparation method of the prescription of any one of claims 1-4, characterized in that, the raw materials are decocted with water, wherein the gypsum is decocted first, and then other traditional Chinese medicine materials are put into and combined for decoction. 6.权利要求1-4任一项所述的方剂在制备具有清肺排毒药效的药物中的应用。6. The application of the prescription of any one of claims 1-4 in the preparation of a medicine with the effect of clearing the lungs and expelling toxins. 7.权利要求1-4任一项所述的方剂在制备治疗肺炎疾病的药物中的应用。7. The application of the prescription of any one of claims 1-4 in the preparation of a medicine for treating pneumonia. 8.根据权利要求7所述的应用，其特征在于，所述肺炎由病毒感染所致。8. The use according to claim 7, wherein the pneumonia is caused by viral infection. 9.根据权利要求8所述的应用，其特征在于，所述病毒包括但不限于新型冠状病毒2019-nCoV、呼吸系统综合症冠状病毒及呼吸道合胞病毒。9. The application according to claim 8, wherein the viruses include but are not limited to novel coronavirus 2019-nCoV, respiratory syndrome coronavirus and respiratory syncytial virus.

CN202010081961.5A 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof Active CN110870402B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202010081961.5A CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof
KR1020227028314A KR20220137663A (en) 2020-02-06 2021-01-26 Chinese medicine complex prescription with detoxification function and its use
CA3168659A CA3168659A1 (en) 2020-02-06 2021-01-26 Traditional chinese medicine compound with lung-clearing and toxin-expelling functions, and application thereof
JP2022546454A JP7424684B2 (en) 2020-02-06 2021-01-26 Chinese herbal medicine complex prescription with lung purifying and detoxifying function and its application
PCT/CN2021/073829 WO2021155751A1 (en) 2020-02-06 2021-01-26 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
TW110103119A TWI792162B (en) 2020-02-06 2021-01-27 A compound traditional Chinese medicine with the function of clearing lung and expelling toxin and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010081961.5A CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Publications (2)

Publication Number Publication Date
CN110870402A true CN110870402A (en) 2020-03-06
CN110870402B CN110870402B (en) 2020-07-17

Family

ID=69660088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010081961.5A Active CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Country Status (6)

Country Link
JP (1) JP7424684B2 (en)
KR (1) KR20220137663A (en)
CN (1) CN110870402B (en)
CA (1) CA3168659A1 (en)
TW (1) TWI792162B (en)
WO (1) WO2021155751A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110824A (en) * 2020-03-26 2020-05-08 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN111154923A (en) * 2020-04-07 2020-05-15 中国医学科学院医学实验动物研究所 Primer for amplifying nucleotide fragment of novel coronavirus (SARS-CoV-2) gene and application thereof
CN111150792A (en) * 2020-03-11 2020-05-15 江苏卫生健康职业学院 Chinese medicinal composition with effect of resisting novel coronavirus SARS-Cov-2, and preparation method and application thereof
CN111202802A (en) * 2020-04-20 2020-05-29 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Traditional Chinese medicine composition for eliminating dampness and ventilating lung and application thereof
CN111214637A (en) * 2020-03-10 2020-06-02 贵州神奇药物研究院 Traditional Chinese medicine composition and preparation method and medicinal application thereof
CN111228423A (en) * 2020-04-02 2020-06-05 湖南补天药业股份有限公司 Pharmaceutical composition applied to novel rehabilitation and nursing of coronavirus pneumonia
CN111265636A (en) * 2020-03-21 2020-06-12 刘彬 A Chinese medicinal composition for treating malignant infectious diseases and preparation method thereof
CN111265586A (en) * 2020-03-16 2020-06-12 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111349719A (en) * 2020-03-09 2020-06-30 广州医科大学附属第一医院（广州呼吸中心） A kind of specific primer and rapid detection method for novel coronavirus detection
CN111437370A (en) * 2020-04-15 2020-07-24 李经纬 Traditional Chinese medicine ointment formula applied to viral influenza and processing method thereof
CN111467451A (en) * 2020-05-11 2020-07-31 劲牌持正堂药业有限公司 Composition and preparation for treating novel coronavirus pneumonia and application of composition and preparation
CN111513378A (en) * 2020-04-03 2020-08-11 枣庄学院 Protective gear for prevention and treatment of novel coronavirus pneumonia in public cultural spaces
CN111537743A (en) * 2020-04-03 2020-08-14 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111529660A (en) * 2020-04-24 2020-08-14 于明华 an antiviral Chinese medicine
CN111557994A (en) * 2020-04-16 2020-08-21 江西浣星谷科技有限公司 Preparation for preventing and adjuvant treating coronavirus infection and preparation method thereof
CN111643646A (en) * 2020-04-26 2020-09-11 北京国梦中和方略科技研究院 Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof
CN111867412A (en) * 2020-04-03 2020-10-30 枣庄学院 Protective gear for prevention and treatment of novel coronavirus pneumonia in public cultural spaces
CN112138133A (en) * 2020-10-23 2020-12-29 成都中医药大学附属医院 Pharmaceutical composition for preventing and/or treating novel coronavirus pneumonia and preparation method and application thereof
CN112515162A (en) * 2020-04-09 2021-03-19 宋交愚 Selenium-enriched additive composition for resisting neocoronarism for areca nuts and preparation method thereof
CN112675282A (en) * 2021-02-02 2021-04-20 王忠兰 Composition for treating pneumonia, preparation method and particles prepared by composition
WO2021155751A1 (en) * 2020-02-06 2021-08-12 中国中医科学院中医临床基础医学研究所 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
CN113332408A (en) * 2021-05-26 2021-09-03 王士红 Lung-clearing and toxin-expelling cigarette
CN113440563A (en) * 2020-03-26 2021-09-28 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
WO2021208334A1 (en) * 2020-04-16 2021-10-21 广东省中医院 Qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and predation method therefor and application thereof
WO2022010424A1 (en) * 2020-07-10 2022-01-13 Kanjanakaroonwong Chaiyaporn Herbal ingredients and manufacturing process for eliminating the coronavirus
CN113952304A (en) * 2021-07-08 2022-01-21 中国中医科学院中医临床基础医学研究所 Qingfei Paidu granules and preparation method thereof
WO2021205083A3 (en) * 2020-04-11 2022-03-10 Finindsutria Srl Composition comprising an antioxidant for the prevention or treatment of covid-19
CN114569652A (en) * 2022-03-22 2022-06-03 深圳市中医院 Traditional Chinese medicine formula of pathogenic-expelling lung-heat-clearing decoction and preparation method thereof
CN115518141A (en) * 2022-05-18 2022-12-27 大连浙香生物科技有限公司 Essential oil for clearing lung and expelling toxin
CN115671191A (en) * 2021-06-25 2023-02-03 牛连贞 Traditional Chinese medicine formula for treating pneumonia

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102526308B1 (en) * 2022-06-23 2023-04-27 한국 한의학 연구원 Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
CN118649200B (en) * 2024-08-15 2024-10-29 江西中医药大学 A Chinese medicinal essential oil composition having the effects of relieving throat, moistening throat and refreshing spirit and its application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549061A (en) * 2008-04-01 2009-10-07 河北以岭医药研究院有限公司 Medicament for treating bronchitis and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09309836A (en) * 1996-05-22 1997-12-02 Taisho Pharmaceut Co Ltd Oral solution
KR101637013B1 (en) * 2014-03-19 2016-07-08 건국대학교 산학협력단 Compositions for Anti-Influenza Virus Comprising Extract of Poncirus trifoliata as Active Ingredients
CN107875278A (en) * 2017-12-08 2018-04-06 江苏师范大学 A kind of Chinese medicine sachet for deficiency of Yin matter crowd's flu-prevention
CN110870402B (en) * 2020-02-06 2020-07-17 葛又文 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549061A (en) * 2008-04-01 2009-10-07 河北以岭医药研究院有限公司 Medicament for treating bronchitis and preparation method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
何永明: "柴苓汤方证研究", 《中国博士学位论文全文数据库 医药卫生辑》 *
曙光健康网: "河北省新型冠状病毒感染的肺炎中医治疗方案（试行第三版）", 《HTTPS://WWW.SG120.COM/ZY/19355.HTML》 *
河北中医药: "河北省新型冠状病毒感染的肺炎中医防治方案（试行第三版）", 《河北中医药管理局官方公众号（河北中医药）》 *
河北省卫生健康委员会、河北省中医药管理局: "河北省新型冠状病毒感染的肺炎诊疗方案（试行第二版）", 《河北省中医药管理局官网》、《河北省卫生健康委员会官网》 *
陈红霞: "四个经方及其合方并用对大鼠哮喘模型嗜酸性粒细胞浸润、凋亡及Fas和Bcl-2表达的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021155751A1 (en) * 2020-02-06 2021-08-12 中国中医科学院中医临床基础医学研究所 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
CN111349719A (en) * 2020-03-09 2020-06-30 广州医科大学附属第一医院（广州呼吸中心） A kind of specific primer and rapid detection method for novel coronavirus detection
CN111214637A (en) * 2020-03-10 2020-06-02 贵州神奇药物研究院 Traditional Chinese medicine composition and preparation method and medicinal application thereof
CN111150792A (en) * 2020-03-11 2020-05-15 江苏卫生健康职业学院 Chinese medicinal composition with effect of resisting novel coronavirus SARS-Cov-2, and preparation method and application thereof
CN111265586A (en) * 2020-03-16 2020-06-12 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111265586B (en) * 2020-03-16 2020-10-20 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111265636A (en) * 2020-03-21 2020-06-12 刘彬 A Chinese medicinal composition for treating malignant infectious diseases and preparation method thereof
WO2021189753A1 (en) * 2020-03-26 2021-09-30 广东省中医院 Pharmaceutical composition for strengthening body and treating lung diseases and application thereof
CN111110824B (en) * 2020-03-26 2020-07-21 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN113440563A (en) * 2020-03-26 2021-09-28 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
CN113440563B (en) * 2020-03-26 2022-09-06 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
CN111110824A (en) * 2020-03-26 2020-05-08 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN111228423A (en) * 2020-04-02 2020-06-05 湖南补天药业股份有限公司 Pharmaceutical composition applied to novel rehabilitation and nursing of coronavirus pneumonia
CN111867412A (en) * 2020-04-03 2020-10-30 枣庄学院 Protective gear for prevention and treatment of novel coronavirus pneumonia in public cultural spaces
CN111513378A (en) * 2020-04-03 2020-08-11 枣庄学院 Protective gear for prevention and treatment of novel coronavirus pneumonia in public cultural spaces
CN111537743B (en) * 2020-04-03 2022-05-03 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111537743A (en) * 2020-04-03 2020-08-14 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111154923A (en) * 2020-04-07 2020-05-15 中国医学科学院医学实验动物研究所 Primer for amplifying nucleotide fragment of novel coronavirus (SARS-CoV-2) gene and application thereof
CN112515162A (en) * 2020-04-09 2021-03-19 宋交愚 Selenium-enriched additive composition for resisting neocoronarism for areca nuts and preparation method thereof
WO2021205083A3 (en) * 2020-04-11 2022-03-10 Finindsutria Srl Composition comprising an antioxidant for the prevention or treatment of covid-19
CN111437370A (en) * 2020-04-15 2020-07-24 李经纬 Traditional Chinese medicine ointment formula applied to viral influenza and processing method thereof
CN111557994A (en) * 2020-04-16 2020-08-21 江西浣星谷科技有限公司 Preparation for preventing and adjuvant treating coronavirus infection and preparation method thereof
WO2021208334A1 (en) * 2020-04-16 2021-10-21 广东省中医院 Qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and predation method therefor and application thereof
WO2021212721A1 (en) * 2020-04-20 2021-10-28 广东省中医院 Traditional chinese medicine composition for dispelling dampness and clearing lung and application thereof
CN111202802A (en) * 2020-04-20 2020-05-29 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Traditional Chinese medicine composition for eliminating dampness and ventilating lung and application thereof
CN111529660A (en) * 2020-04-24 2020-08-14 于明华 an antiviral Chinese medicine
CN111643646A (en) * 2020-04-26 2020-09-11 北京国梦中和方略科技研究院 Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof
CN111467451A (en) * 2020-05-11 2020-07-31 劲牌持正堂药业有限公司 Composition and preparation for treating novel coronavirus pneumonia and application of composition and preparation
WO2022010424A1 (en) * 2020-07-10 2022-01-13 Kanjanakaroonwong Chaiyaporn Herbal ingredients and manufacturing process for eliminating the coronavirus
CN112138133B (en) * 2020-10-23 2021-10-19 成都中医药大学附属医院 Pharmaceutical composition for treating novel coronavirus pneumonia and preparation method and application thereof
CN112138133A (en) * 2020-10-23 2020-12-29 成都中医药大学附属医院 Pharmaceutical composition for preventing and/or treating novel coronavirus pneumonia and preparation method and application thereof
CN112675282A (en) * 2021-02-02 2021-04-20 王忠兰 Composition for treating pneumonia, preparation method and particles prepared by composition
CN113332408A (en) * 2021-05-26 2021-09-03 王士红 Lung-clearing and toxin-expelling cigarette
CN115671191A (en) * 2021-06-25 2023-02-03 牛连贞 Traditional Chinese medicine formula for treating pneumonia
CN113952304A (en) * 2021-07-08 2022-01-21 中国中医科学院中医临床基础医学研究所 Qingfei Paidu granules and preparation method thereof
CN114569652A (en) * 2022-03-22 2022-06-03 深圳市中医院 Traditional Chinese medicine formula of pathogenic-expelling lung-heat-clearing decoction and preparation method thereof
CN115518141A (en) * 2022-05-18 2022-12-27 大连浙香生物科技有限公司 Essential oil for clearing lung and expelling toxin

Also Published As

Publication number Publication date
KR20220137663A (en) 2022-10-12
WO2021155751A1 (en) 2021-08-12
CN110870402B (en) 2020-07-17
TW202140053A (en) 2021-11-01
JP7424684B2 (en) 2024-01-30
CA3168659A1 (en) 2021-08-12
TWI792162B (en) 2023-02-11
JP2023512529A (en) 2023-03-27

Similar Documents

Publication Publication Date Title
CN110870402B (en) Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof
CN102614440B (en) Multi-herb antibacterial liquid
CN101461911B (en) A traditional Chinese medicinal capsule for treating gout
CN100540034C (en) A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN104173704A (en) Traditional Chinese medicine decoction for treating subacute thyroiditis
CN101653529A (en) Medicine for treating allergic rhinitis
CN101439164A (en) Preparation method of traditional Chinese medicine for treating excessive-fire type aphtha
CN111110819A (en) Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza
CN100402075C (en) Pharynx clearing tea
CN101045091B (en) Traditional Chinese medicine decoction for treating acute toothache
CN101664524A (en) Medicament for treating paranasal sinusitis and preparation method thereof
CN104784548A (en) Traditional Chinese medicine composition for treating cough and application thereof
CN100482270C (en) Lotion of compound flavescent sophora root for treating disease in department of gynecology, and preparation method
CN104208545A (en) Traditional Chinese medicine preparation for treating pruritus vulvae and preparation method of traditional Chinese medicine preparation
CN101293073B (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus
CN101138613A (en) Traditional Chinese medicine for treating acute bronchitis of children
CN103599421B (en) Traditional Chinese medicine composition for treating halitosis
CN103611027B (en) The pharmaceutical composition of a kind of clinical prevention, nursing and treatment trichomonal vaginitis
CN116139237A (en) A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application
CN105395941A (en) A heat clearing and detoxifying traditional Chinese medicine oral liquid
HK40026270B (en) Traditional chinese medicine prescription capable of treating covid-19 and application thereof
HK40026270A (en) Traditional chinese medicine prescription capable of treating covid-19 and application thereof
CN110251564A (en) A kind of externally applied drug and preparation method thereof for treating gouty arthritis
CN102048871A (en) Formula of traditional Chinese medicine for treating renal calculus
CN100486631C (en) Chinese traditional medicinal formula for treating AIDS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026270

Country of ref document: HK